Popular Articles

Statement About Agreement With White House And Senate Finance Committee On Health Reform
America"s hospitals have long been committed to expanding coverage to the millions of
generic viagra online
New Study Finds Social And Economic Factors Play Major Role In Determining Who Gets Bariatric Surgery
Less than one-half of one percent (0.4%) of the 22 million people in the U.S. who are medically eligible for bariatric surgery actually get the surgery, and those who do are most likely to be white females with higher incomes and covered by private health insurance, according to a new study presented here at the 26th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
News of the day
Screening Of First-Degree Relatives Of Patients With Bicuspid Aortic Valve Recommended
Bicuspid Aortic Valve (BAV), a condition in which patients" aortic valves have just two leaflets instead of the normal three, is the most common cardiac anomaly, affecting up to two percent of the general population. The defect can result in calcification deposits on the heart valve, leakage of the valve and may results in a feeling of tightness in the chest as well as shortness of breath. The condition is easily diagnosed; often physicians can hear a "click" or a murmur when they listen to a BAV patient"s heart with a stethoscope.
Endocrinology

Eye Drug Trial Marks Milestone For Southampton's Groundbreaking Research Centre, UK

Eye experts based at Southampton General Hospital are trialling a drug that could repair vision without the need for surgery. Andrew Lotery, professor of ophthalmology at the University of Southampton and consultant ophthalmologist at Southampton Eye Unit, and his team are studying an experimental drug called Microplasmin in patients with focal vitreomacular adhesion. The condition means the centre of the eye has an unusually strong connection to the retina, which can cause vessel and retinal distortion and result in deterioration of sight. Researchers will evaluate the safety and effectiveness of the drug when injected directly into the eye. Early clinical studies have shown that the injection could potentially tackle vitreomacular adhesion effectively without the risks associated with surgery and may have a part to play in treating other sight-threatening conditions. The study is the 500th to take place at the Wellcome Trust Clinical Research Facility (WTCRF) at Southampton General Hospital. Since opening in 2001, the WTCRF has supported the translational clinical research of the city"s best scientists and investigators, involving over 32,000 patients and volunteers. Using specialist facilities and teams of trained research nurses, some of the country"s top experts are working to develop new treatments and methods of delivering care. Research is conducted in a wide range of diseases and conditions, including asthma, cancer, food allergies, infectious diseases, blindness and arthritis. Professor Lotery said: "Southampton Eye Unit has worked with Wellcome Trust research nurses in 24 studies over the last six years. "This has led to significant research breakthroughs and many patients have had their sight saved by being enrolled in our studies. My research programme would not be possible without the WTCRF." Originally funded by the UK"s largest charity, the Wellcome Trust, the WTCRF is a partnership between Southampton University Hospitals NHS Trust and the University of Southampton. Dr Saul Faust, consultant paediatrician and director of the WTCRF, said: "It is fantastic that the centre is able to support ground breaking research such as Andrew"s that has such a positive impact on patient care. We are looking forward to yet more success in the future as we expand our activities in partnership with all our investigators, collaborators and research participants. "The strength of our staff team is key to our growth and I would like to thank them all for their dedication and hard work." Southampton University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):